Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

CDC backs Pfizer’s COVID-19 vaccine for 5- to 11-year-olds

By Brian Buntz | November 2, 2021

Pfizer-BioNTechThe Comirnaty vaccine from Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) could soon be available for children between the ages of 5 and 11, now that CDC has backed its use.

CDC Director Dr. Rochelle P. Walensky formally authorized the vaccine after the Advisory Committee on Immunization Practices (ACIP) unanimously recommended its use.

“We know millions of parents are eager to get their children vaccinated and with this decision, we now have recommended that about 28 million children receive a COVID-19 vaccine,” Walensky said.

The members of the CDC have “a lot of enthusiasm for this vaccine in this age group,” said Dr. Beth Bell, an ACIP member and professor at the University of Washington.

The vaccine will be available to younger children at the 10-μg dose level, which is one-third as much as the amount in the version for individuals 12 and up.

Earlier this week, the White House signaled that the federal government had acquired enough Pfizer vaccine for all children aged 5 to 11.

The federal government plans to partner with a network of schools, pediatricians, family doctors and other facilities to administer the vaccine.

In a Pfizer Phase 3 trial, the vaccine had 91% efficacy against symptomatic COVID-19.

Last week, FDA’s Vaccines and Related Biological Products Advisory Committee also voted in favor of authorizing the vaccine in younger children.

On October 29, FDA authorized the vaccine for children between the ages of 5 to 11.

American Medical Association praised the support for vaccinating younger children. “We are hopeful that millions of children will receive the vaccine in the coming weeks and months—significantly reducing their risk of COVID-19 infection, hospitalization, and death, and bringing the end of the pandemic closer,” said AMA President Dr. Gerald E. Harmon, in a statement.

Harmon also pushed for equitable vaccination of children, explaining that hospitalization rates are three times higher for some ethnic groups compared with white children. “Ensuring equitable access to the pediatric vaccine will be critical, including through school located clinics,” Harmon said.


Filed Under: Drug Discovery, Infectious Disease
Tagged With: BioNTech, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50